Studies related to Interleukin 10 and Coenzyme Q10

Oral Coenzyme Q10 Supplementation In Patients With Migraine: Effects On Clinical Features And Inflammatory Markers

Effect Increase
Values (ng/l). Mean and SD. Placebo: before 38.98 ± 22.85, after 46.00 ± 26.98. Intervention: before 47.10 ± 28.69, after 56.29 ± 37.55.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 45
Sex Female
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 45 premenopausal women with episodic migraine were allocated to take 400 mg of coq10 daily or placebo for 3 months.

Migraine frequency, severity, and duration were all reduced significantly more than placebo. Calcitonin gene-related peptide and tumor necrosis factor were reduced significantly more in the coq10 group, while IL-6 was reduced nonsignificantly more, and IL-10 increased nonsignificantly more.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.